ROCKVILLE, Md., Aug. 19, 2008 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) today announced that The Wall Street Transcript (TWST) has published an in-depth interview with Chief Executive Officer Martin Rosendale. The interview, which was published in the August 18th issue of TWST, is available on the Cytomedix web site (www.cytomedix.com) or to subscribers at TWST's web site (www.twst.com).
During the interview, Mr. Rosendale noted that following the launch earlier this year of the Company's proprietary AutoloGel(tm) System, a point-of-care system for the management of chronic wounds, his priority remains advancing sales of the AutoloGel(tm) System and working with the Company's sales executives "to initiate commercial contracts, facilitate payment and reimbursement opportunities, and move the sales of the AutoloGel(tm) System forward," Mr. Rosendale said.
In addition to the Company's work in chronic wounds, Mr. Rosendale reported that Cytomedix has identified compounds with related properties such as angiogenesis, the production of blood vessels, and anti-inflammatory properties. "We recently announced that we are developing a peptide, CT-112, which is an anti-inflammatory peptide that may be active for the treatment of inflammatory diseases such as Rheumatoid Arthritis, Crohn's Disease, Tissue Reperfusion Injury and other related medical conditions," Mr. Rosendale added.
Mr. Rosendale also stated that the Company's long term vision is to achieve a leadership position in the field of advanced tissue regeneration technologies. "Cytomedix will continue to develop and market products that support the needs of patients with debilitating and life-threatening conditions. Our clinical success will result from the logical application of sophisticated biological therapies to treat complex clinical problems, and our commercial success will be a result of an intense focus on therapies with sound pharmacoeconomic benefits," he added.
ABOUT CYTOMEDIX
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, and competitive responses. CT-112 was introduced as a therapeutic candidate with an FDA Pre-IND meeting in 1995. It is uncertain whether the company will obtain the funds necessary for development, or whether current market conditions will support a renewed effort to develop CT-112. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.